Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease.
Wanderer
Alan A
AA
University of Colorado Health Sciences Center, Aurora, CO, USA. aw@aacmt.com
D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D006461:Hemolysis; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors* / Q000097:blood*; D009569:Nitric Oxide / Q000097:blood; D010641:Phenotype; D015427:Reperfusion Injury / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology
D053583:Interleukin-1beta; D009569:Nitric Oxide